SHELTON CAPITAL MANAGEMENT - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
SHELTON CAPITAL MANAGEMENT ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q2 2021$969,000
+17.9%
2,1530.0%0.04%
+27.6%
Q1 2021$822,000
+20.2%
2,1530.0%0.03%
-6.5%
Q4 2020$684,000
+24.4%
2,153
-3.0%
0.03%
+34.8%
Q3 2020$550,000
-6.1%
2,2200.0%0.02%
-28.1%
Q2 2020$586,000
+32.3%
2,220
-4.9%
0.03%0.0%
Q1 2020$443,000
-17.7%
2,335
-4.7%
0.03%
+6.7%
Q4 2019$538,000
+7.4%
2,450
-4.4%
0.03%0.0%
Q3 2019$501,000
-6.2%
2,5620.0%0.03%
-3.2%
Q2 2019$534,000
-79.8%
2,562
+387.1%
0.03%
+210.0%
Q1 2019$2,648,000
+591.4%
526
-80.1%
0.01%
-61.5%
Q4 2018$383,000
-29.1%
2,6480.0%0.03%
-16.1%
Q3 2018$540,000
+37.8%
2,6480.0%0.03%
+29.2%
Q2 2018$392,000
-2.0%
2,6480.0%0.02%
-7.7%
Q1 2018$400,000
+9.6%
2,648
-6.1%
0.03%
+13.0%
Q4 2017$365,000
+7.0%
2,8210.0%0.02%0.0%
Q3 2017$341,000
+3.0%
2,8210.0%0.02%0.0%
Q2 2017$331,000
+15.3%
2,8210.0%0.02%
+15.0%
Q1 2017$287,000
-23.1%
2,821
-22.3%
0.02%
-28.6%
Q4 2016$373,000
-6.0%
3,6290.0%0.03%
-15.2%
Q3 2016$397,000
-2.9%
3,6290.0%0.03%
-8.3%
Q2 2016$409,000
+19.2%
3,6290.0%0.04%
+16.1%
Q1 2016$343,000
+4.9%
3,6290.0%0.03%
-3.1%
Q4 2015$327,000
-2.7%
3,6290.0%0.03%
-13.5%
Q3 2015$336,000
-5.9%
3,6290.0%0.04%0.0%
Q2 2015$357,000
-1.9%
3,6290.0%0.04%
-5.1%
Q1 2015$364,000
+8.7%
3,6290.0%0.04%0.0%
Q4 2014$335,0003,6290.04%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2020
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders